Changes of TSH-Stimulation Blocking Antibody (TSBAb) and Thyroid Stimulating Antibody (TSAb) Over 10 Years in 34 TSBAb-Positive Patients with Hypothyroidism and in 98 TSAb-Positive Graves’ Patients with Hyperthyroidism: Reevaluation of TSBAb and TSAb in TSH-Receptor-Antibody (TRAb)-Positive Patients
The changes of TSAb in 98 Graves’ patients with hyperthyroidism (II) (Table 1, II). Among the 98 Graves’ patients with hyperthyroidism, 10 patients continued to have persistently positive TSAb and continued to have hyperthyroidism (Table 1, IIa) (a). Ten of the 98 TSAb-positive Graves’ patients with hyperthyroidism continued to have persistently positive TSAb. They continued to have hyperthyroidism and did not get remissions of Graves’ hyperthyroidism. They continued to take MMI. Complex changes of TSAb were noted in 13 TSAb-positive patients (Table 1, IIb) (b). One of the 13 patients with complex changes of TSAb got remissions, but the other 12 patients did not get remissions. TSAb disappeared in 73 (74%) of the 98 TSAb-positive Graves’ patients with hyperthyroidism (Table 1, IIc) (c). With the disappearance of TSAb, 60 (82%) of the 73 patients, in whom TSAb had disappeared, got remissions of Graves’ hyperthyroidism. (d1, d2) show the changes of TSAb and TSBAb, respectively, in the 2 patients with TSAb-positive Graves’ hyperthyroidism, who developed TSBAb-positive hypothyroidism (Table 1, IId). In these 2 patients, TSAb was dominant initially (d1), and then TSBAb became dominant (d2). Two patients with TSAb-positive Graves’ hyperthyroidism developed TSBAb-positive hypothyroidism. Graves’ hyperthyroidism was treated with MMI, and hypothyroidism was treated with T4.
Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.